vimarsana.com
  1. Home
  2. Live Updates
  3. Hangzhou Sciwind Biosciences Co - Breaking News

Page 3 - Hangzhou Sciwind Biosciences Co News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity

/PRNewswire/ Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat.

New zealandSciwind biosciencesThai panPrnewswire sciwind biosciences co ltdHangzhou sciwind biosciences coHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

/PRNewswire/ Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat.

Thai panPrnewswire sciwind biosciences co ltdHangzhou sciwind biosciences co

Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

/PRNewswire/ Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat.

Thai panPrnewswire sciwind biosciences co ltdHangzhou sciwind biosciences co

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.